As Biotechnology companies, Cara Therapeutics Inc. (NASDAQ:CARA) and XBiotech Inc. (NASDAQ:XBIT) are our subject to contrast. And more specifically their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cara Therapeutics Inc.	7.94M	78.88	67.54M	-1.18	0.00
XBiotech Inc.	N/A	0.00	22.28M	-0.65	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Cara Therapeutics Inc. and XBiotech Inc.

Profitability

Table 2 shows us Cara Therapeutics Inc. and XBiotech Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cara Therapeutics Inc.	-850.63%	-70.8%	-50.9%
XBiotech Inc.	0.00%	-41.4%	-39.5%

Volatility and Risk

Cara Therapeutics Inc. is 193.00% more volatile than S&P 500 because the stock has a beta of 2.93. XBiotech Inc.’s 86.00% less volatile than S&P 500 which is a result of the 0.14 beta.

Liquidity

The Current Ratio and a Quick Ratio of Cara Therapeutics Inc. are 4.9 and 4.9. Competitively, XBiotech Inc. has 9.3 and 9.3 for Current and Quick Ratio. XBiotech Inc.’s better ability to pay short and long-term obligations than Cara Therapeutics Inc.

Analyst Recommendations

In next table is shown Cara Therapeutics Inc. and XBiotech Inc.’s ratings and recommendations.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Cara Therapeutics Inc.	0	1	4	2.80
XBiotech Inc.	0	0	0	0.00

Cara Therapeutics Inc.’s upside potential currently stands at 58.79% and an $25.2 consensus target price.

Insider and Institutional Ownership

Roughly 61.2% of Cara Therapeutics Inc. shares are held by institutional investors while 4.3% of XBiotech Inc. are owned by institutional investors. About 2.9% of Cara Therapeutics Inc.’s share are held by insiders. Insiders Comparatively, held 9.5% of XBiotech Inc. shares.

Performance

In this table we provide the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Cara Therapeutics Inc.	-12.93%	-19.69%	-21.56%	-3.12%	21.12%	29.33%
XBiotech Inc.	-7.59%	4.55%	48.92%	-3.04%	-7.38%	5.08%

For the past year Cara Therapeutics Inc. was more bullish than XBiotech Inc.

Summary

On 6 of the 10 factors XBiotech Inc. beats Cara Therapeutics Inc.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companyÂ’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.